Oxford Ledge
Search
Biogen Inc. (NASDAQ: BIIB) is a $33.2B drug manufacturers - general company trading at $224.51 — 25.5× trailing earnings. Figures from SEC EDGAR and market feeds; updated 2026-09-04 12:38 UTC.
Biogen is a global biopharmaceutical company that discovers, develops and delivers medicines for serious and complex diseases, with particular focus on neurology, specialized immunology and rare diseases. The company markets multiple medicines for multiple sclerosis, spinal muscular atrophy, Friedreich's ataxia and amyotrophic lateral sclerosis, and has collaborations on Alzheimer's disease and postpartum depression treatments.
Summarized from Biogen Inc.’s SEC filings · Read the filing ↗
| Quote | |
| Price | $224.51 |
| Market cap | $33.2B |
| Volume | 550.7K shares |
| 52-week range | $179.15 – $225.80 |
| Valuation | |
| P/E (TTM) | 25.54× |
| EPS (TTM) | $8.79 |
| Returns | |
| 52-week return | +25.3% |
Biogen is a global biopharmaceutical company that discovers, develops and delivers medicines for serious and complex diseases, with particular focus on neurology, specialized immunology and rare diseases.
BIIB trades at $224.51, 25.54× trailing earnings, as of 2026-09-04.
Biogen Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-01. All filings link to their SEC EDGAR originals above.
SEC EDGAR filings and public market data feeds, fetched 2026-09-04 12:38 UTC. This page is also available as JSON at /api/data?ticker=BIIB and is emitted with FAQPage structured data for machine reading.
Charts, 10-year financials, peer comparison, screening and portfolio tracking for BIIB and 5,000+ tickers.
Create a free account — keep BIIBGET /api/data?ticker=BIIB
This page as JSON via rel="alternate" · REST API docs · MCP server (59 tools) · llms.txt